Gut · 2025-10-06
P36 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis (PBC) with two years of treatment with elafibranor
Phrase rank #1 · DOI 10.1136/gutjnl-2025-BASL.52
Other observed topics
week
Observed in 109 articles across 27 journals.
Latest share0.04%
Change vs baseline-0.32 pp
Months observed13
Latest monthJul 2026
Portfolio article share
Attention over this snapshot
13 monthly points
Journal breadth
Where it appears
- BMJ24
- Gut17
- BMJ Open7
- Lupus Science & Medicine7
- RMD Open7
- Thorax6
- Journal of Neurology, Neurosurgery & Psychiatry5
- British Journal of Sports Medicine3
- European Journal of Hospital Pharmacy3
- Heart3
- Journal of Scleroderma and Related Disorders3
- Archives of Disease in Childhood2
Co-occurrence
Explore nearby topics
Inspect the source signal
Article evidence
30 high-ranking examples
Gut · 2026-06-23
O62 Randomised controlled trial of withdrawal of thiopurines when switching from intravenous to subcutaneous infliximab: results of the MINIMISE study
Phrase rank #2 · DOI 10.1136/gutjnl-2026-BSG.61
Gut · 2026-06-23
P216 Real-world effectiveness and safety of etrasimod in ulcerative colitis: interim analysis of the EFFECT-UC study
Phrase rank #2 · DOI 10.1136/gutjnl-2026-BSG.338
Thorax · 2025-11-02
P197 Dupilumab causes improvements in spirometry ratios in patients with moderate-to-severe asthma, which correlate with changes in fractional exhaled nitric oxide and asthma control
Phrase rank #2 · DOI 10.1136/thorax-2025-BTSabstracts.378
Lupus Science & Medicine · 2025-10-29
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study
Phrase rank #2 · DOI 10.1136/lupus-2025-001689
Gut · 2026-06-23
P170 Symptomatic relief and disease clearance with 50 weeks tulisokibart treatment in moderate to severe ulcerative colitis in phase 2 ARTEMIS-UC
Phrase rank #3 · DOI 10.1136/gutjnl-2026-BSG.298
Journal of Scleroderma and Related Disorders · 2026-06-05
P.267 Tibusure: a phase 2, global, randomized, double-blind, placebo-controlled study with open-label extension to evaluate the efficacy, safety, and tolerability of tibulizumab in systemic sclerosis
Phrase rank #3 · DOI 10.1136/JSRD-2026-SSWC.310
RMD Open · 2026-05-12
Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J)
Phrase rank #3 · DOI 10.1136/rmdopen-2025-006446
European Journal of Hospital Pharmacy · 2026-03-18
4CPS-002 Importance of individualising isankizumab treatment in patients with Crohn’s disease
Phrase rank #3 · DOI 10.1136/ejhpharm-2026-eahp.107
Emergency Medicine Journal · 2026-02-24
A Week in Emergency
Phrase rank #3 · DOI 10.1136/emermed-2025-215706
Heart · 2025-12-08
O1 Is 150 minutes per week of moderate to vigorous physical activity a potential ‘over prescription’ for cardiac rehabilitation? A systematic analysis of trials in the cochrane review
Phrase rank #3 · DOI 10.1136/heartjnl-2025-BACPR.1
RMD Open · 2025-10-22
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
Phrase rank #3 · DOI 10.1136/rmdopen-2025-005969
BMJ Open Gastroenterology · 2026-03-23
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis
Phrase rank #4 · DOI 10.1136/bmjgast-2025-002153
European Journal of Hospital Pharmacy · 2026-03-18
3PC-005 Stability testing of low-concentration atropine formulations for ophthalmic use
Phrase rank #4 · DOI 10.1136/ejhpharm-2026-eahp.68
BMJ · 2025-10-31
“Unusually early” flu seasons sees 250 hospital admissions in a week
Phrase rank #4 · DOI 10.1136/bmj.r2299
Gut · 2025-10-06
P26 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE® trial
Phrase rank #4 · DOI 10.1136/gutjnl-2025-BASL.42
Gut · 2026-06-26
IDDF2026-ABS-0040 Early gut microbiome stagnation and specific taxonomic signatures precede late-onset sepsis in preterm infants: a longitudinal case-control study
Phrase rank #5 · DOI 10.1136/gutjnl-2026-IDDF.233
British Journal of Sports Medicine · 2026-06-12
Long-term resistance training with all-cause and cause-specific mortality: assessing dose-response and joint associations with aerobic physical activity
Phrase rank #5 · DOI 10.1136/bjsports-2025-110503
Archives of Disease in Childhood - Fetal and Neonatal Edition · 2026-04-29
Probiotics for extremely preterm infants: a Norwegian population-based study
Phrase rank #5 · DOI 10.1136/archdischild-2025-330176
RMD Open · 2026-01-08
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies
Phrase rank #5 · DOI 10.1136/rmdopen-2025-005867
Archives of Disease in Childhood · 2025-08-18
Contact with the National Health Service in the week after an acute medical paediatric admission
Phrase rank #5 · DOI 10.1136/archdischild-2024-328208
Gut · 2026-06-23
P280 Reducing on-call burden while increasing specialty exposure: impact of a redesigned gastroenterology specialty doctor rota
Phrase rank #6 · DOI 10.1136/gutjnl-2026-BSG.394
Lupus Science & Medicine · 2026-03-01
PO:11:280 Randomized, placebo-controlled, double-blind phase 1b/2 study to explore safety, pharmacokinetics, and initial efficacy of DS-7011a, an anti-toll-like receptor 7 monoclonal antibody, in SLE patients
Phrase rank #6 · DOI 10.1136/lupus-2026-el.334
BMJ Open · 2025-11-12
Effects of combined haemodialysis-haemoadsorption therapy in maintenance haemodialysis patients: study protocol for a multicentre, open-label, randomised, parallel controlled trial
Phrase rank #6 · DOI 10.1136/bmjopen-2025-107017
Thorax · 2025-11-02
M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective
Phrase rank #6 · DOI 10.1136/thorax-2025-BTSabstracts.498
Gut · 2025-10-06
P31 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis (PBC): proteomic results from the ELATIVE® trial
Phrase rank #6 · DOI 10.1136/gutjnl-2025-BASL.47
Gut · 2025-09-08
Hepatomegaly and ascites in a patient with UC
Phrase rank #6 · DOI 10.1136/gutjnl-2024-333587
British Journal of Sports Medicine · 2025-08-26
How much running is too much? Identifying high-risk running sessions in a 5200-person cohort study
Phrase rank #6 · DOI 10.1136/bjsports-2024-109380
BMJ · 2026-07-09
General purpose AI . . . and other research
Phrase rank #7 · DOI 10.1136/bmj-2026-100107
Gut · 2026-06-23
O14 Improvement in health-related quality of life in non-cirrhotic and cirrhotic patients with MASLD treated with resmetirom: data from MAESTRO-NAFLD
Phrase rank #7 · DOI 10.1136/gutjnl-2026-BSG.14